Dystonic camptocormia: clinical presentation, diagnosis, and treatment results

Cover Page


Cite item

Full Text

Abstract

This study was aimed at assessing clinical features of camptocormia as one of the symptoms of dystonia and evaluating the effectiveness of various treatments for this condition. The study involved 39 patients with dystonia and camptocormia symptoms. We analyzed the clinical features of dystonic camptocormia, evaluated the results of pharmacotherapy and botulinum therapy, as well as neuromodulation methods, namely transcranial magnetic stimulation and deep brain stimulation. It was shown that phased and integrated approach is required to manage patients with camptocormia caused by dystonic hyperkinesis. Local injection of botulinum toxin and deep brain stimulation are the most effective treatments. More extensive use of low-frequency transcranial magnetic stimulation may be advisable for everyday practical use in patients with dystonic prosternation.

About the authors

S. A. Likhachev

Republican Scientific and Practical Center of Neurology and Neurosurgery of the Ministry of Health of Belarus

Email: tatyana_ch@fromru.com
Belarus, Minsk

T. N. Chernukha

Republican Scientific and Practical Center of Neurology and Neurosurgery of the Ministry of Health of Belarus

Author for correspondence.
Email: tatyana_ch@fromru.com
Belarus, Minsk

G. V. Zabrodets

Republican Scientific and Practical Center of Neurology and Neurosurgery of the Ministry of Health of Belarus

Email: tatyana_ch@fromru.com
Belarus, Minsk

O. V. Gleb

Republican Scientific and Practical Center of Neurology and Neurosurgery of the Ministry of Health of Belarus

Email: tatyana_ch@fromru.com
Belarus, Minsk

V. V. Alekseevets

Republican Scientific and Practical Center of Neurology and Neurosurgery of the Ministry of Health of Belarus

Email: tatyana_ch@fromru.com
Belarus, Minsk

V. S. Terekhov

Republican Scientific and Practical Center of Neurology and Neurosurgery of the Ministry of Health of Belarus

Email: tatyana_ch@fromru.com
Belarus, Minsk

References

  1. Иллариошкин С.Н., Маркова Е.Д., Миклина Н.И., Иванова-Смоленская И.А. Молекулярная генетика наследственных дистонических синдромов. Журн. неврол. и психиатрии им. С.С.Корсакова. 2000; 8: 60–66.
  2. Коваленко А.П. Использование ботулинотерапии для лечения камптокормии у пациентов с болезнью Паркинсона (клинический случай). В сб.: Болезнь Паркинсона и расстройства движений. Руководство для врачей по материалам III Нац. конгресса.M.: Соверо пресс, 2014: 198–200.
  3. Руководство пользователя «Программно-методическое обеспе чение компьютерного стабилометрического комплекса StabMed 2.0». Таганрог: ЗАО «ОКБ Ритм», 2004.
  4. Albanese A. EFNS guidelines on diagnosis and treatment of primary dystonias J. Eur. J. Neurol. 2011; 18: 5–18.
  5. Albanese A., Bhatia K., Bressman S.B. Phenomenology and classification of dystonia: a consensus update. Mov. Disord. 2013; 28: 863–873.
  6. Azher S.N., Jankovic J. Сamptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005; 65: 355–359.
  7. Bloch F., Houeto J.L., Tezenas du Montcel S. et al. Parkinson’s disease with camptocormia. J. Neurol. Neurosurg. Psychiatry. 2006; 77:1223–1228.
  8. Delcey V., Hachulla E., Michon-Pasturel U. et al. Camptocormia: a sign of axial myopathy. Report of 7 cases. Rev. Med. Interne. 2002; 23:144–154.
  9. Dressier D. Botulinum Toxin Therapy. Stuttgart: Thieme-Verlag, 2000.
  10. Fietzek U.M., Schroeteler F.E., Ceballos-Baumann A.O. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov. Disord. 2009; 24: 2027–2028.
  11. Finsterer J., Strobl W. Presentation, Etiology, diagnosis, and management of camptocormia. Eur. Neurol. 2010; 64: 1–8.
  12. Gómez-Puerta J.A., Peris P., Grau J.M. et al. Camptocormia as a clinical manifestation of mitochondrial myopathy. Clin. Rheumatol. 2007; 26: 1017–1019.
  13. Grigoriu A.I., Dinomais M., Rémy-Néris O. et al. Impact of injectionguiding techniques on the effectiveness of botulinum toxin for the treatment of focal spasticity and dystonia: a systematic review. Arch. Phys. Med. Rehabil. 2015; 96: 2067–2078.
  14. Hachulla E. Dermatomyositis and polymyositis: clinical aspects and treatment. Ann. Med. Interne. 2001; 152: 455–464.
  15. Illarioshkin S.N., Markova E.D., Slominsky P.A. et al. The GTP cyclohydrolase I gene in Russian families with dopa-responsive dystonia. Arch. Neurol. 1998; 55: 789–792.
  16. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon. 2009; 54: 614–623.
  17. Karbowski K. The old and the new camptocormia. Spine. 1999; 24: 1494–1498.
  18. Kim J.M., Song E.J., Seo J.S. et al. Polymyositis-like syndrome caused by hypothyroidism, presenting as camptocormia. Rheumatol. Int. 2009; 29: 339–342.
  19. Kumar H., Jog M. Peripheral trauma induced dystonia or post-traumatic syndrome? Can. J. Neurol. Sci. 2011; 38: 22–29.
  20. Lepoutre A.C., Devos D., Blanchard-Dauphin A. et al. A specific clinical pattern of camptocormia in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry. 2006; 77: 1229–1234.
  21. Loseth S., Voermans N.C., Torbergsen T. et al. A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene. J. Neurol. 2013; 260: 1504–1510.
  22. Lyons M.K. Deep brain stimulation: current and future clinical applications. Mayo Clin. Proc. 2011; 86: 662–672.
  23. Ma H., McEvoy K.M., Milone M. Sporadic inclusion body myositis presenting with severe camptocormia. J. Clin. Neurosci. 2013; 20: 1628–1629.
  24. Melamed E., Djaldetti R. Camptocormia in Parkinson’s disease. J. Neurol. 2006; 253: 14–16.
  25. Mezaki T. Clinical characteristics and treatment of dystonia. Rinsho Shinkeigaku. 2011; 51: 465–470.
  26. Ohana M., Durand M.C., Marty C. et al. Whole-body muscle MRI to detect myopathies in non-extrapyramidal bent spine syndrome. Skeletal. Radiol. 2014; 43: 1113–1122.
  27. Reichel G., Kirchhöfer U., Stenner A. Camptocormia – segmental dystonia. Proposal of a new definition for an old disease. Nervenarzt. 2001; 72: 281–285.
  28. Skidmore F., Anderson K., Fram D. et al. Psychogenic camptocormia. Mov Disord. 2007; 22: 1974–1975.
  29. Srivanitchapoom P., Hallett M.J. Camptocormia in Parkinson’s disease: definition, epidemiology, pathogenesis and treatment modalities. Neurol. Neurosurg. Psychiatry. 2015; 87: 75–85.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Likhachev S.A., Chernukha T.N., Zabrodets G.V., Gleb O.V., Alekseevets V.V., Terekhov V.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies